Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 16/20 | 0.59 |
| ▸ | SCTR | P47872 | 1/20 | 0.59 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581278 | 0.94 | GLP1R (0.64) | GLP1R | |
| SCHEMBL29582112 | 0.94 | GLP1R (0.64) | GLP1R | |
| SCHEMBL29581449 | 0.91 | GLP1R (0.66) | GLP1R | |
| SCHEMBL31026560 | 0.90 | NPY4R (0.54) | GLP1RSCTRNPY1RNPY2RNPY4R | |
| SCHEMBL31182719 | 0.87 | GLP1R (0.68) | GLP1RSCTRTFPI | |
| SCHEMBL31222393 | 0.87 | NPY4R (0.61) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30538628 | 0.87 | TFPI (0.68) | GLP1RSCTRTFPI | |
| SCHEMBL30262097 | 0.87 | GLP1R (0.59) | GLP1RSCTRKEAP1 | |
| SCHEMBL29658174 | 0.86 | GLP1R (0.62) | GLP1RSCTRTFPI | |
| SCHEMBL29622989 | 0.86 | GLP1R (0.65) | GLP1RSCTRTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143196-A1 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | MC1R, MC3R, MCHR1 | GLP1R 64/4885SCTR 43/4885TFPI 4098/4885 |
| US-12440570-B2 | Conjugation of MCR1 ligand with cytotoxic drugs for treating skin cancer | MC1R, MC3R, MCHR1 | GLP1R 64/4885SCTR 43/4885TFPI 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.